U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
  • The following terms were not found in MedGen: Dimethylaminomethyl, quinolin, 5-Dimethylaminomethyl-quinolin-8-ol.

pentostatin

MedGen UID:
10633
•Concept ID:
C0030896
•
Antibiotic; Nucleic Acid, Nucleoside, or Nucleotide
Synonyms: 2' Deoxycoformycin; 2'-Deoxycoformycin; Deoxycoformycin; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (R)-; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)-; Pentostatin
SNOMED CT: Pentostatin (387154004); Deoxycoformycin (387154004); Pentostatin-containing product (28149003)
Drug response:
Pentostatin response
MedGen UID:
982456
•Concept ID:
CN298613
•
Sign or Symptom
Pentostatin response

Definition

A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2''-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04) [from NCI]

Professional guidelines

PubMed

Novel treatment strategies in chronic lymphocytic leukemia.
Weiss MA
Curr Oncol Rep 2001 May;3(3):217-22. doi: 10.1007/s11912-001-0053-0. PMID: 11296131
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB, Nahata MC
Drug Saf 2000 Apr;22(4):263-302. doi: 10.2165/00002018-200022040-00002. PMID: 10789823
Purine analogues in the management of lymphoproliferative diseases.
Johnson SA
Clin Oncol (R Coll Radiol) 1996;8(5):289-96. doi: 10.1016/s0936-6555(05)80714-9. PMID: 8934048

Recent clinical studies

Etiology

Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA
Curr Oncol Rep 2023 Aug;25(8):833-840. Epub 2023 Apr 25 doi: 10.1007/s11912-023-01419-z. PMID: 37097545Free PMC Article
Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
Else M, Dearden CE, Catovsky D
Best Pract Res Clin Haematol 2015 Dec;28(4):217-29. Epub 2015 Oct 9 doi: 10.1016/j.beha.2015.09.004. PMID: 26614900Free PMC Article
Treatment of T-Cell lymphoma.
Hotta T
Hematology 2005;10 Suppl 1:193-6. doi: 10.1080/10245330512331390393. PMID: 16188671
Hypersensitivity reactions.
Weiss RB
Semin Oncol 1992 Oct;19(5):458-77. PMID: 1384149
Treatment of hairy-cell leukemia.
Lill MC, Golde DW
Blood Rev 1990 Dec;4(4):238-44. doi: 10.1016/0268-960x(90)90003-b. PMID: 1706207

Diagnosis

Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA
Curr Oncol Rep 2023 Aug;25(8):833-840. Epub 2023 Apr 25 doi: 10.1007/s11912-023-01419-z. PMID: 37097545Free PMC Article
Hairy Cell Leukaemia.
Cross M, Dearden C
Curr Oncol Rep 2020 Apr 16;22(5):42. doi: 10.1007/s11912-020-00911-0. PMID: 32297104
Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma 2019 Dec;60(12):2869-2879. Epub 2019 May 9 doi: 10.1080/10428194.2019.1608536. PMID: 31068044Free PMC Article
T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma 2009;9 Suppl 3:S239-43. doi: 10.3816/CLM.2009.s.018. PMID: 19778847
Chronic graft-versus-host disease.
Bolaños-Meade J, Vogelsang GB
Curr Pharm Des 2008;14(20):1974-86. doi: 10.2174/138161208785061373. PMID: 18691108

Therapy

Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ, Pastan I
Biomolecules 2020 Aug 3;10(8) doi: 10.3390/biom10081140. PMID: 32756468Free PMC Article
Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma 2019 Dec;60(12):2869-2879. Epub 2019 May 9 doi: 10.1080/10428194.2019.1608536. PMID: 31068044Free PMC Article
T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma 2009;9 Suppl 3:S239-43. doi: 10.3816/CLM.2009.s.018. PMID: 19778847
Treatment of T-Cell lymphoma.
Hotta T
Hematology 2005;10 Suppl 1:193-6. doi: 10.1080/10245330512331390393. PMID: 16188671
Hypersensitivity reactions.
Weiss RB
Semin Oncol 1992 Oct;19(5):458-77. PMID: 1384149

Prognosis

Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA
Curr Oncol Rep 2023 Aug;25(8):833-840. Epub 2023 Apr 25 doi: 10.1007/s11912-023-01419-z. PMID: 37097545Free PMC Article
Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ, Pastan I
Biomolecules 2020 Aug 3;10(8) doi: 10.3390/biom10081140. PMID: 32756468Free PMC Article
Hairy Cell Leukaemia.
Cross M, Dearden C
Curr Oncol Rep 2020 Apr 16;22(5):42. doi: 10.1007/s11912-020-00911-0. PMID: 32297104
Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma 2019 Dec;60(12):2869-2879. Epub 2019 May 9 doi: 10.1080/10428194.2019.1608536. PMID: 31068044Free PMC Article
T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma 2009;9 Suppl 3:S239-43. doi: 10.3816/CLM.2009.s.018. PMID: 19778847

Clinical prediction guides

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I
Leuk Lymphoma 2011 Jun;52 Suppl 2(Suppl 2):82-6. doi: 10.3109/10428194.2011.565843. PMID: 21599609Free PMC Article
Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas.
Grever MR
Leuk Lymphoma 2011 Jun;52 Suppl 2:25-8. doi: 10.3109/10428194.2011.577851. PMID: 21599604
Modern strategies for hairy cell leukemia.
Grever MR, Lozanski G
J Clin Oncol 2011 Feb 10;29(5):583-90. Epub 2011 Jan 10 doi: 10.1200/JCO.2010.31.7016. PMID: 21220590
Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Huynh E, Sigal D, Saven A
Leuk Lymphoma 2009 Oct;50 Suppl 1:12-7. doi: 10.3109/10428190903142083. PMID: 19814692
Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms.
Mitchell BS, Kelley WN
Ann Intern Med 1980 Jun;92(6):826-31. doi: 10.7326/0003-4819-92-6-826. PMID: 6247948

Recent systematic reviews

PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP.
Nachat A, Turoff-Ortmeyer S, Liu C, Mcculloch M
Perm J 2016 Spring;20(2):74-80. doi: 10.7812/TPP/15-153. PMID: 27168399Free PMC Article
Purine antagonists for chronic lymphocytic leukaemia.
Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R
Cochrane Database Syst Rev 2006 Jul 19;2006(3):CD004270. doi: 10.1002/14651858.CD004270.pub2. PMID: 16856041Free PMC Article
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R; Cochrane Haematologic Malignancies Group
Cancer Treat Rev 2006 Aug;32(5):377-89. Epub 2006 Jun 21 doi: 10.1016/j.ctrv.2006.05.002. PMID: 16793209

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • MeSH
      Related Medical Subject Headings
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...